Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29221023 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2HSD17B10KMT2AALDH1A1OGFRL1 | |
| SCHEMBL29221025 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2HSD17B10KMT2AALDH1A1OGFRL1 | |
| SCHEMBL10209181 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2AMALT1 | |
| SCHEMBL10209176 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2HSD17B10KMT2AALDH1A1OGFRL1 | |
| SCHEMBL11055247 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10KMT2AALDH1A1MAPT | |
| SCHEMBL9105161 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2HSD17B10KMT2AALDH1A1OGFRL1 | |
| SCHEMBL9105152 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2HSD17B10KMT2AALDH1A1OGFRL1 | |
| SCHEMBL3836397 | 0.77 | SMN1; SMN2 (0.48) | SMN1; SMN2HSD17B10KMT2AALDH1A1OGFRL1 | |
| SCHEMBL4881098 | 0.76 | DYRK1A (0.48) | SMN1; SMN2HSD17B10KMT2AALDH1A1MAPT | |
| SCHEMBL21853236 | 0.75 | SMN1; SMN2 (0.56) | SMN1; SMN2HSD17B10KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| EP-1786786-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006025783-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ADORA1, P2RX1, P2RY1 | SMN1; SMN2 3067/4885HSD17B10 4456/4885KMT2A 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.